Royal Bank Of Canada Forecasts Strong Price Appreciation for Hinge Health (NYSE:HNGE) Stock

Hinge Health (NYSE:HNGE) had its target price raised by research analysts at Royal Bank Of Canada from $110.00 to $135.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price suggests a potential upside of 16.01% from the company’s current price.

Several other analysts have also commented on HNGE. Stifel Nicolaus increased their price target on shares of Hinge Health from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. Citizens Jmp lifted their price objective on shares of Hinge Health from $96.00 to $107.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 5th. Needham & Company LLC boosted their price objective on shares of Hinge Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley raised their target price on shares of Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, Weiss Ratings downgraded Hinge Health from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.20.

Hinge Health Trading Up 0.8%

Shares of NYSE:HNGE traded up $0.89 on Tuesday, reaching $116.37. The company had a trading volume of 330,439 shares, compared to its average volume of 1,618,864. Hinge Health has a 52-week low of $30.08 and a 52-week high of $118.86. The firm’s 50 day simple moving average is $98.66 and its 200-day simple moving average is $67.35. The firm has a market capitalization of $9.39 billion, a PE ratio of 91.44 and a beta of 1.37.

Hinge Health (NYSE:HNGE) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.44. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. The firm had revenue of $234.97 million during the quarter. During the same quarter last year, the company earned ($0.02) earnings per share. The company’s revenue for the quarter was up 52.4% compared to the same quarter last year. As a group, equities research analysts predict that Hinge Health will post 1.25 earnings per share for the current year.

Insider Activity at Hinge Health

In other Hinge Health news, CEO Daniel Perez sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $89.44, for a total transaction of $13,416,000.00. Following the sale, the chief executive officer owned 35,470 shares of the company’s stock, valued at approximately $3,172,436.80. The trade was a 80.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Gabriel Mecklenburg sold 250,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $88.97, for a total transaction of $22,242,500.00. Following the sale, the chairman directly owned 250,000 shares in the company, valued at approximately $22,242,500. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,024,581 shares of company stock worth $95,632,761. 18.92% of the stock is owned by insiders.

Institutional Investors Weigh In On Hinge Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. SBI Securities Co. Ltd. lifted its stake in Hinge Health by 39.5% during the 3rd quarter. SBI Securities Co. Ltd. now owns 364 shares of the company’s stock valued at $35,000 after acquiring an additional 103 shares during the period. ProShare Advisors LLC increased its stake in shares of Hinge Health by 2.1% in the third quarter. ProShare Advisors LLC now owns 5,588 shares of the company’s stock worth $543,000 after acquiring an additional 117 shares during the period. IFP Advisors Inc raised its holdings in shares of Hinge Health by 140.0% during the second quarter. IFP Advisors Inc now owns 324 shares of the company’s stock worth $27,000 after purchasing an additional 189 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Hinge Health by 3.3% during the first quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company’s stock worth $362,000 after purchasing an additional 300 shares during the last quarter. Finally, Nykredit A S acquired a new position in Hinge Health during the second quarter valued at $29,000.

Hinge Health News Summary

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Record Q3 results beat expectations. Hinge Health reported third-quarter revenue of approximately $235.0 million, up 52.4% year over year and ahead of the roughly $224.8 million consensus estimate. Adjusted earnings were reported at $0.71 per share, exceeding consensus forecasts ranging from $0.27 to $0.63. The company also posted a 15.15% net margin and 51.6% return on equity. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: Revenue guidance was raised above Wall Street expectations. Hinge Health forecast fourth-quarter 2026 revenue of $249.0 million to $251.0 million, versus consensus of $239.2 million. Full-year 2026 revenue guidance of $879.0 million to $881.0 million also exceeded the $858.5 million consensus estimate. Hinge Health 2026 revenue outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings. Canaccord Genuity increased its price target from $105 to $134 and assigned a “buy” rating. Stifel Nicolaus raised its target from $130 to $135 and also rated the stock “buy,” implying roughly 16% to 17% potential upside from recent levels.
• Positive Sentiment: Future growth initiatives provided an additional catalyst. Management is targeting an integrated gastrointestinal program for summer 2027, supporting the broader expansion of Hinge Health’s digital-care platform.
• Neutral Sentiment: The stock is trading near its 52-week high after a substantial advance, with a high valuation reflected in a price-to-earnings ratio near 90. Although the earnings and outlook were strong, the elevated valuation may limit further gains if results do not continue to exceed already-high expectations.

Hinge Health Company Profile

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.